Hypoxia-tropic Protein Nanocages for Modulation of Tumor- and Chemotherapy-Associated Hypoxia.
Antineoplastic Agents
/ administration & dosage
Cell Hypoxia
Cell Line, Tumor
Cisplatin
/ administration & dosage
Ferritins
/ chemistry
Fluorescent Dyes
/ chemistry
Humans
Nanocapsules
/ chemistry
Neoplasms
/ metabolism
Oxygen
/ metabolism
Polyethylene Glycols
/ chemistry
Spheroids, Cellular
/ metabolism
HIF-1α
PEGylation
drug resistance
ferritin nanocage
hypoxia
tumor penetration
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
22 01 2019
22 01 2019
Historique:
pubmed:
24
12
2018
medline:
22
1
2020
entrez:
22
12
2018
Statut:
ppublish
Résumé
Despite its central role in tumor progression and treatment resistance, poor vascularization that necessitates penetration of therapeutics through tumor extracellular matrix (ECM) constitutes a significant challenge to managing tumor hypoxia via conventional systemic treatment regimens. In addition, methods to target hypoxic tumor cells are lacking. Here, we discovered that human ferritin nanocages (FTn) possess an intrinsic ability to preferentially engage with hypoxic tumor tissues, in addition to normoxic tumor areas. We also developed a simple method of endowing FTn with spatially controlled "mosaic" surface poly(ethylene glycol) (PEG) coatings that facilitate deep penetration of FTn through ECM to reach hypoxic tumor tissues while retaining its inherent hypoxia-tropic property. Hypoxia-inhibiting agents systemically delivered via this surface-PEGylated FTn were readily accumulated in hypoxic tumor tissues, thereby providing significantly enhanced therapeutic benefits compared to the identical agents delivered in solution as a stand-alone therapy or an adjuvant to restore efficacy of conventional systemic chemotherapy.
Identifiants
pubmed: 30576113
doi: 10.1021/acsnano.8b05399
pmc: PMC8323471
mid: NIHMS1726351
doi:
Substances chimiques
Antineoplastic Agents
0
Fluorescent Dyes
0
Nanocapsules
0
Polyethylene Glycols
3WJQ0SDW1A
Ferritins
9007-73-2
Cisplatin
Q20Q21Q62J
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-247Subventions
Organisme : NEI NIH HHS
ID : P30 EY001765
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125169
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127413
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL136617
Pays : United States
Références
Nat Rev Cancer. 2006 Aug;6(8):583-92
pubmed: 16862189
Nucleic Acids Res. 1999 Nov 1;27(21):4223-7
pubmed: 10518614
J Biol Chem. 2008 Jul 25;283(30):20674-86
pubmed: 18519569
ACS Nano. 2016 Oct 25;10(10):9243-9258
pubmed: 27666558
ACS Nano. 2018 May 22;12(5):4105-4115
pubmed: 29608290
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3505-10
pubmed: 20133674
J Control Release. 2018 Jul 28;282:13-24
pubmed: 29522833
PLoS One. 2011;6(8):e23800
pubmed: 21886823
J Exp Med. 2005 Oct 3;202(7):955-65
pubmed: 16203866
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Adv Healthc Mater. 2015 May;4(7):1023-33
pubmed: 25761435
Xenobiotica. 2005 Jul;35(7):755-73
pubmed: 16323364
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14900-5
pubmed: 25267615
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23
pubmed: 26512116
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38
pubmed: 25453096
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Drug Deliv. 2017 Dec;24(sup1):22-32
pubmed: 29069920
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
J Biol Chem. 1999 Aug 20;274(34):24142-6
pubmed: 10446187
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8720-5
pubmed: 26124127
Carcinogenesis. 2014 Aug;35(8):1671-9
pubmed: 24903340
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5
pubmed: 19805192
J Control Release. 2017 Sep 28;262:37-46
pubmed: 28694032
Lab Invest. 2006 Aug;86(8):767-80
pubmed: 16732297
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
PLoS One. 2014 Jun 05;9(6):e98882
pubmed: 24901645
Cancer Res. 2002 Jun 15;62(12):3387-94
pubmed: 12067980
Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6595-E6602
pubmed: 28739953
Cancer Res. 1984 Jul;44(7):3090-7
pubmed: 6373002
Nat Rev Cancer. 2008 Jun;8(6):425-37
pubmed: 18500244
Sci Adv. 2017 Apr 05;3(4):e1601556
pubmed: 28435870
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Semin Thromb Hemost. 2010 Apr;36(3):321-31
pubmed: 20490982
Eur J Cancer. 1999 May;35(5):808-14
pubmed: 10505043
Bioinformatics. 2016 Apr 15;32(8):1229-31
pubmed: 26656931
Sci Transl Med. 2012 Aug 29;4(149):149ra119
pubmed: 22932224
J Cell Biol. 1970 Nov 1;47(2):500-11
pubmed: 19866747
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
Microvasc Res. 2000 Jan;59(1):24-37
pubmed: 10625568
J Biol Chem. 1996 Jul 26;271(30):17771-8
pubmed: 8663540
J Am Chem Soc. 2006 Dec 27;128(51):16626-33
pubmed: 17177411
Nat Nanotechnol. 2012 Jun 17;7(7):459-64
pubmed: 22706697
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
Nano Lett. 2011 Feb 9;11(2):814-9
pubmed: 21210706
J Biol Chem. 1999 Aug 20;274(34):24147-52
pubmed: 10446188
ACS Nano. 2013 Aug 27;7(8):6988-96
pubmed: 23829542
Am J Physiol Cell Physiol. 2009 Dec;297(6):C1567-75
pubmed: 19828835